Toll-like receptor polymorphisms in allogeneic hematopoietic cell transplantation

Biol Blood Marrow Transplant. 2015 Feb;21(2):259-65. doi: 10.1016/j.bbmt.2014.09.016. Epub 2014 Nov 20.

Abstract

To assess the impact of the genetic variation in toll-like receptors (TLRs) on outcome after allogeneic myeloablative conditioning hematopoietic cell transplantation (HCT), we investigated 29 single nucleotide polymorphisms across 10 TLRs in 816 patients and donors. Only donor genotype of TLR8 rs3764879, which is located on the X chromosome, was significantly associated with outcome at the Bonferroni-corrected level P ≤ .001. Male hemizygosity and female homozygosity for the minor allele were significantly associated with disease-free survival (hazard ratio [HR], 1.47 [95% confidence interval {CI}, 1.16 to 1.85]; P = .001). Further analysis stratified by donor sex due to confounding by sex was suggestive for associations with overall survival (male donor: HR, 1.41 [95% CI, 1.09 to 1.83], P = .010; female donor: HR, 2.78 [95% CI, 1.43 to 5.41], P = .003), disease-free survival (male donor: HR, 1.45 [95% CI, 1.12 to 1.87], P = .005; female donor: HR, 2.34 [95% CI, 1.18 to 4.65], P = .015), and treatment-related mortality (male donor: HR, 1.49 [95% CI, 1.09 to 2.04], P = .012; female donor: HR, 3.12 [95% CI, 1.44 to 6.74], P = .004). In conclusion, our findings suggest that the minor allele of TLR8 rs3764879 of the donor is associated with outcome after myeloablative conditioned allogeneic HCT.

Keywords: Allogeneic hematopoietic cell transplantation; Single nucleotide polymorphism; Toll-like receptor 8; Toll-like receptors.

Publication types

  • Observational Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Alleles
  • Child
  • Child, Preschool
  • Chromosomes, Human, X / chemistry
  • Female
  • Gene Expression
  • Genotype
  • Graft vs Host Disease / prevention & control
  • Hematologic Neoplasms / immunology
  • Hematologic Neoplasms / mortality*
  • Hematologic Neoplasms / pathology
  • Hematologic Neoplasms / therapy
  • Hematopoietic Stem Cell Transplantation / mortality*
  • Hemizygote
  • Homozygote
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • Myeloablative Agonists / therapeutic use
  • Polymorphism, Single Nucleotide*
  • Prognosis
  • Sex Factors
  • Survival Analysis
  • Tissue Donors
  • Toll-Like Receptor 8 / genetics*
  • Toll-Like Receptor 8 / immunology
  • Transplantation Conditioning*
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Myeloablative Agonists
  • TLR8 protein, human
  • Toll-Like Receptor 8